Biora Therapeutics shared positive topline results from a trial of its orally administered drug-device combination for treating ulcerative colitis (UC). BT-600, a proprietary liquid formulation of tofacitinib, is delivered directly to the colon using Biora’s ingestible NaviCap device. Biora designed NaviCap to improve patient outcomes by enabling therapeutic delivery directly to the site of the […]
